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Background: Although widespread reduced white mat-
ter (WM) integrity is a consistent finding in cross-
sectional diffusion tensor imaging (DTI) studies of 
schizophrenia, little is known about the course of  these 
alterations. This study examined to what degree micro-
structural WM alterations display differential trajecto-
ries over time as a function of  level of  psychosis liability. 
Methods: Two DTI scans with a 3-year time interval 
were acquired from 159 participants (55 patients with 
a psychotic disorder, 55 nonpsychotic siblings and 49 
healthy controls) and processed with tract-based spatial 
statistics. The mean fractional anisotropy (FA) change 
over time was calculated. Main effects of  group, as 
well as group × region interactions in the model of  FA 
change were examined with multilevel (mixed-effects) 
models. Results: Siblings revealed a significant mean FA 
decrease over time compared to controls (B = −0.004, 
P = .04), resulting in a significant sibling-control differ-
ence at follow-up (B = −0.007, P = .03). Patients did not 
show a significant change over time, but their mean FA 
was lower than controls both at baseline and at follow-
up. A significant group × region interaction (χ2 = 105.4, 
P  =  .01) revealed group differences in FA change in 
the right cingulum, left posterior thalamic radiation, 
right retrolenticular part of  the internal capsule, and 
the right posterior corona radiata. Conclusion: Whole 
brain mean FA remained stable over a 3-year period in 
patients with psychotic disorder and declined over time 
in nonaffected siblings, so that at follow-up both groups 
had lower FA with respect to controls. The results sug-
gest that liability for psychosis may involve a process of 
WM alterations.
Key words: psychotic disorder/diffusion tensor 
imaging/disease progression/siblings
Introduction
The functional dysconnectivity hypothesis of schizo-
phrenia suggests that symptoms originate as a result of 
miscommunication between different brain areas,1,2 associ-
ated with microstructural white matter (WM) alterations. 
Diffusion tensor imaging (DTI) is used to identify poten-
tial WM microstructural correlates. Fractional anisotropy 
(FA) combines information on myelination, fiber density, 
and number of axons in 1 measure, whereas additional dif-
fusion parameters (axial-, radial-, and mean diffusivity) 
may provide more specific information on WM integrity.3 
A large number of cross-sectional DTI studies of patients 
in early and later stages of schizophrenia have shown 
decreased FA with respect to controls in several WM tracts 
throughout the brain.4,5 However, it is not clear when these 
WM alterations occur and how they develop over time.6 
Both a neurodevelopmental model,7,8 implying that WM 
alterations are present before disease onset and a postonset 
progression model, indicating that structural brain abnor-
malities progress over time after disease onset, have been 
proposed.9,10 In support of the neurodevelopmental model, 
several cross-sectional DTI studies have revealed micro-
structural WM alterations in frontotemporal and -parietal 
connections in first-degree relatives without symptoms,11,12 
in clinical high-risk populations before onset,13,14 and 
in patients with early onset psychosis.15 Indeed, the life-
time trajectory of WM alterations in schizophrenia sug-
gests higher percentages of WM loss in the first years of 
D
ow
nloaded from
 https://academ
ic.oup.com
/schizophreniabulletin/article/43/1/160/2503405 by U
niversiteit M
aastricht user on 09 O
ctober 2020
161
Differential Time Course of Microstructural White Matter
the illness, implicating altered neurodevelopment.6,16 The 
literature on longitudinal WM changes, however, is too 
limited to draw firm conclusions on neurodevelopmental 
or progressive changes, as well as the role of medication.16 
A study by Carletti and colleagues (2012) showed a signifi-
cant progressive reduction in FA in the left frontal WM in 
individuals at “Ultra-High Risk” (UHR) who developed 
psychosis compared to UHR subjects who did not make a 
“transition”.17 Reis Marques and colleagues (2014) found 
an increase in FA in first episode patients (both respond-
ers and nonresponders to antipsychotic [AP] medication) 
over a 12-week period,18 and Garver and colleagues (2008) 
reported reduced mean diffusivity after 28 days of treat-
ment in drug-responding patients with schizophrenia, 
which was not found in nonresponders.19 A fourth study 
compared WM FA changes between individuals during a 
more chronic course of schizophrenia (n = 49) and healthy 
controls (n  =  16), reporting a stronger FA decline over 
4 years in frontal, temporal, and parietal WM in the con-
trols. A subgroup of patients with poor outcome could be 
differentiated from a group with good outcome by regional 
progression of WM alterations in an adjacent precentral/
postcentral area.20
Not only DTI, but also longitudinal volumetric stud-
ies are scarce. Decreases over time have been described in 
recent onset and first-episode patients in frontal lobe WM 
volume21 and temporal lobe WM volume, respectively.22 
However, in patients aged up to 51 years, van Haren and 
colleagues (2008) described an abnormal curved trajec-
tory of volume change, with normalization of age-related 
volume change later in life.23
In our recent cross-sectional diffusion analyses of 
patients with a psychotic disorder, siblings and controls 
(n = 258), patient-specific microstructural WM alterations 
were found in the corpus callosum and other WM tracts.24 
This sample was re-scanned approximately 3 years later to 
examine whether the evolution of FA over time varies as a 
function of familial risk for psychotic disorder.
Methods
Participants
Participants were recruited in the context of a multi-
center longitudinal study (Genetic Risk and Outcome of 
Psychosis, G.R.O.U.P.) in the Netherlands.25 The mag-
netic resonance imaging (MRI) add-on study was con-
ducted in Maastricht, the Netherlands (see Domen and 
colleagues24 or the Supplemental Method section for 
full information on in- and exclusion criteria of the par-
ticipants and diagnostic assessments). For the baseline 
MRI study, 300 participants were included of which 258 
provided a valid DTI scan: 85 patients with a psychotic 
disorder, 93 siblings without a psychotic disorder, and 
80 healthy controls. At follow-up, approximately 3 years 
later (mean: 3.3 year), a second DTI scan was acquired 
from 180 participants (loss to follow-up of 40%). The 
final sample comprised 159 participants (55 patients with 
a psychotic disorder, 55 siblings without a psychotic dis-
order, and 49 healthy controls), for which a pair of DTI 
scans was available for longitudinal analysis (table 1).
The sample included 129 families of which 16 families 
contributed 1 patient and 1 healthy sibling and 1 family con-
tributed 1 patient and 2 healthy siblings. Six families con-
tributed 2 healthy siblings, 1 family contributed 3 healthy 
siblings, and 4 families contributed 2 healthy controls. In 
addition, 38 families contributed 1 patient, 22 families con-
tributed 1 sibling, and 41 families contributed 1 control.
The standing ethics committee approved the study pro-
tocol, and all participants gave written informed consent 
in accordance with the committee’s guidelines.
Measures
Symptoms. At both time points, symptoms were 
assessed with the Positive and Negative Syndrome Scale 
(PANSS).26 The 5-factor model by van der Gaag and col-
leagues (2006) was used, dividing the PANSS in positive 
symptoms, negative symptoms, disorganization symp-
toms, excitement, and emotional distress.27 The scores of 
the individual items of the 5 symptom dimensions were 
summed. To assess clinical remission, the operationalized 
criteria described by Andreasen and colleagues (2005)28 
were applied.
Educational level (at baseline) was defined as the high-
est accomplished level of education. Handedness was 
assessed using the Annett Handedness Scale.29
Medication. In the patient group, AP medication use 
was determined by patient report and verified with the 
treating consultant psychiatrist. Best estimate lifetime 
(cumulative) AP use at baseline was determined by multi-
plying the number of days of AP use with the correspond-
ing haloperidol equivalents and summing these scores 
for all periods of AP use (including the exposure period 
between baseline assessment for the G.R.O.U.P.  study 
and the moment of baseline MRI scanning), using the 
published converting formulas for AP dose equivalents 
described by Andreasen and colleagues.30 The same pro-
cedure was used for calculating cumulative AP exposure 
during the 3-year follow-up period.
Substance Use. Substance use was measured at both time 
points with the Composite International Diagnostic Interview 
(CIDI) sections B-J-L.31 Alcohol use was defined as the 
reported number of weekly consumptions during the last 
12 months. As data on drug use of the last 3 years were not 
available, cannabis and other drugs were assessed as reported 
frequency of use during the last 12 months, as well as lifetime 
use. CIDI frequency data on alcohol, lifetime cannabis, and 
other drug use were available at baseline for respectively 158 
participants (1% missing data), 155 participants (3% missing 
data), and 157 participants (1% missing data).
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Image Acquisition
MRI scans were obtained at Maastricht University, the 
Netherlands, using an Allegra Magnetom MR (Siemens) 
operating at 3.0 Tesla. At both measurement points, micro-
structural anatomy was examined using DTI with an echo-
planar-imaging sequence (field of view 230 × 230 mm2, TR 
10 800 ms, TE 84 ms, voxel size 1.8 × 1.8 × 1.8 mm3, b-value 
1000 s/mm2, 85 slices, no overlap). As a result of a scan-
ner update at the baseline measurement, 2 DTI sequences 
were used: one with 76 directions (of which 4 diffusion-
unweighted [B0] and 72 diffusion-weighted [B1000]) and 
one with 81 directions (8xB0 and 73xB1000). A potential 
association between the proportion of baseline scans and 
group was investigated using a Pearson chi-square test. 
At follow-up, the DTI sequence comprised 81 directions 
(8xB0 and 73xB1000). Total acquisition time of the DTI 
sequence was 15 minutes.
DTI Analysis
DTI data were processed using tract-based spatial statis-
tics (TBSS) v1.2 in FSL 4.1.6 (FMRIB Analysis Group, 
http://www.fmrib.ox.ac.uk/analysis/research/tbss). First, 
standard Siemens DICOM files were transformed into 
compressed NIFTI format using a custom built in-house 
software named GIANT (General Image ANalysis Tools 
developed by E.G.). Raw data were corrected for head 
movement and eddy currents invoked during scanning. 
The B0 volume was skull-stripped using FSL’s Brain 
Extraction Tool32 and this served as a brain mask for all 
B volumes.
The next step was fitting a diffusion tensor model at 
each voxel using data output from the brain extraction, 
diffusion weighted data, and gradient directions follow-
ing a general linear model (FreeSurfer v4.5.0, http://www.
freesurfer.net). After tensor fitting (using the DT-Recon 
script) the process continued working on FA volumes, 
eroding them slightly. Nonlinear registration aligned 
each FA volume to 1 × 1 × 1 mm standard FMRIB58_FA 
space. The standard FMRIB58_FA contains a template 
derived from high-resolution images of 58 participants in 
a well-aligned population (both males and females rang-
ing between 20 and 50 years of age).33
After nonlinear transformation of the FA volumes 
into standard space, 2 mean FA skeletons were created; 
(1) one based on 3 groups (n  =  159: controls, siblings, 
Table 1. Demographic Characteristics of the Participants (n = 159)
Controls (n = 49) Siblings (n = 55) Patients (n = 55)
Time Point 0 1 0 1 0 1
Scan interval (d) 1222 ± 198 1177 ± 101 1196 ± 121
Age at scan (y) 31.0 ± 11.0 34.4 ± 10.9 30.9 ± 8.5 34.1 ± 8.5 28.7 ± 6.3 32.0 ± 6.2
Sex, male (%) 19 (39%) 29 (53%) 40 (73%)
Handedness 83.2 78.0 72.2
Level of education 5.4 ± 2.0 5.4 ± 2.1 4.5 ± 1.9
Age of onset (y) — — 21.8 ± 6.3
Illness duration (y) — — 5.7 ± 3.5 10.3 ± 4.0
AP medication — — 6693 ± 6254a 5335 ± 5715b
Diagnosis
 Schizophrenia — — 33
 Schizoaffective disorder — — 16
 Psychotic disorder NOS — — 6
 Major depressive disorderc 11 15 —
Substance use
 Cannabis 4.8 ± 32.0d 7.1 ± 49.1d 36.5 ± 105.2d
 Other drugs 0.0 0.0 15.2 ± 57.0d
 Alcohol 6.3 ± 10.8e 6.0 ± 5.4e 4.9 ± 7.6e
PANSS scores
 Positive symptoms 7.3 ± 1.2 7.4 ± 0.8 7.4 ± 0.9 7.4 ± 0.7 9.6 ± 3.7 11.6 ± 5.7
 Negative symptoms 8.2 ± 1.2 8.0 ± 0.2 8.2 ± 1.3 8.0 ± 0.3 11.4 ± 5.2 11.1 ± 4.2
 Disorganization 10.3 ± 1.5 10.1 ± 0.3 10.3 ± 0.6 10.1 ± 0.4 11.7 ± 2.6 11.8 ± 2.5
 Excitement 8.4 ± 1.3 8.3 ± 0.5 8.5 ± 1.2 8.3 ± 0.6 9.4 ± 1.9 9.7 ± 2.5
 Emotional distress 9.3 ± 2.1 9.4 ± 1.7 9.7 ± 2.2 9.7 ± 2.2 12.9 ± 5.2 14.1 ± 5.0
Remission (percentage) — — — — 61% 62%
Note: Means ± SDs are reported. AP, antipsychotic; NOS, not otherwise specified; PANSS, Positive and Negative Syndrome Scale.
aCumulative exposure (in haloperidol equivalents), lifetime until baseline assessment.
bExposure (in haloperidol equivalents) over last 3 y.
cHistory of major depressive disorder, no current episodes at baseline or in last 3 y.
dMean number of times; last 12 mo.
eWeekly consumptions last 12 mo.
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patients) for the cross-sectional analysis at follow-up and 
(2) one based on 6 groups (3 groups × 2 time-points) for 
the longitudinal analysis. The mean FA skeleton follows 
the major WM tracts in each individual participant (nor-
malized in MNI152 space) and provides a way to com-
pare between (groups of) participants. The FA threshold 
was set, using visual inspection of the FA skeleton, at a 
level of 0.25, to include major WM tracts whilst remov-
ing small peripheral tracts that would cause excess inter-
participant variability. In addition, this threshold setting 
avoided inclusion of regions that are likely to be com-
posed of multiple tissue types or fiber orientations. In the 
final step, a binary skeleton mask was created and used 
to extract FA values of the individual participants. The 
Johns Hopkins University International Consortium for 
Brain Mapping (JHU ICBM)-DTI-81 WM atlas labels34 
were used to label all voxels and assign a specific tract 
name. If  the voxels did not match with the JHU ICBM 
labels, they were identified using the JHU WM tractog-
raphy atlas.35
Statistical Analyses
From the 38 JHU labeled WM tracts, skeleton mean FA 
values per participant per time point were extracted and 
exported to R (version 3.2.0), a free software environ-
ment for statistical computing and graphics.36
Longitudinal Analyses. Within-group paired t-tests 
were done to examine the difference in regional mean 
FA between baseline and follow-up. Subsequently, a 
mean FA “change” (delta, Δ per participant per region) 
was calculated by subtracting mean FA (baseline) from 
mean FA (follow-up). The data set was transformed from 
a wide to a hierarchically structured data set, with 38 
regional ΔFA measures (Level 1) nested in subjects (Level 
2) who were part of the same families (Level 3). A mixed- 
effects model was used to examine the model with ΔFA 
measures as the dependent variable and scan-interval 
as additional covariate. In addition, since the outcome 
represents means based on varying number of voxels 
(depending on the region), we used a model in which the 
error variance for a particular observation was inversely 
weighted by the number of voxels within the correspond-
ing region (ie, since the variance of a mean is equal to 
the variance of a single observation—in this case voxel—
divided by the number of values used for the averaging). 
Main effects of group, corrected for age, sex, handedness, 
level of education and scan-interval, as well as group × 
sex and group × region interactions in the model of ΔFA 
were examined. In each of the 38 regions, between-group 
factor significance was tested. Regions with a significant 
group effect were examined with pairwise comparisons 
(ie, it was tested whether ΔFA differed between patients 
and controls, between siblings and controls, and between 
patients and siblings).
Due to the large number of regions (and hence tests), 
Simes’ procedure37,38 was used to control the false discov-
ery rate when testing the regional within-group mean FA 
differences between baseline and follow-up, the between-
group effects within the 38 regions, and the pairwise 
comparisons.
Sensitivity analyses were performed with last year can-
nabis use, lifetime cannabis use, and scan type (76 or 81 
directions) as additional covariates in 3 separate models. 
Since a subgroup of participants in the control (n = 11) 
and sibling group (n = 15) had a history of a depressive 
disorder (and a number of DTI studies with patients with 
a major depressive disorder have shown decreased FA in 
several cortical and subcortical WM tracts39), additional 
sensitivity analyses were conducted controlling for his-
tory of depression.
AP Medication. In patients only, the association 
between ΔFA and respectively last 3-year and lifetime 
AP use was examined. These variables were entered 
both as linear and as factored variables (ie, represent-
ing the distribution of  scores divided by its tertiles: low, 
moderate, or high AP exposure), allowing visualization 
of  dose-response. Sensitivity analyses were done using 
patient subgroups (with low, moderate, and high AP 
exposure), ie, the association between group and ΔFA 
was examined per AP subgroup to examine whether 
patients with differential AP exposure would have dif-
ferential FA change over time in comparison to controls 
and siblings.
Cross-sectional Analyses at Follow-up. To examine 
group differences at follow-up (n = 159), a whole-brain 
mean FA was computed with the 38 WM regions con-
form the above-described procedure. Whole-brain FA 
was the dependent variable and random effects (inter-
cepts) were added for each subject and family, including a 
priori hypothesized confounding variables age, sex, hand-
edness, and level of education as fixed effects.
Results
Participant Characteristics
The characteristics of the 159 individuals with a baseline 
and follow-up scan are displayed in table 1. The majority 
of the patients were not in need of inpatient care or inten-
sive treatment, as reflected by the low PANSS scores at 
both time points and the proportion of patients in remis-
sion. At baseline, 54 patients were receiving AP medica-
tion with a mean dosage in terms of standard haloperidol 
equivalents of 5.4 milligrams (mg) (SD = 3.4). At follow-
up, 45 patients used AP medication (second generation: 
n = 42; first generation: n = 3), with a mean dosage of 
4.7 mg (SD = 5.1). The lifetime cumulative AP exposure 
was 13079.7 mg (SD = 10977.2).
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The proportion of baseline scans with 76 directions did 
not differ between the groups (84% in controls, 82% in 
siblings, and 71% in patients: χ2 = 3.02, df = 2, P = .22).
Whole Brain Group Differences in FA Change Over 
Time (ΔFA)
The mean ΔFA revealed a slight increase over time in 
the controls (0.001) and a decrease over time in the sib-
lings (−0.003) and patients (−0.0002), with the mean FA 
(0.504) of the siblings at follow-up in between that of the 
controls (0.509) and the patients (0.502) (figure 1). At fol-
low-up, there were more WM tracts showing a decrease 
than an increase in patients and siblings (27 and 23 of the 
38 tracts, respectively), whereas in controls the propor-
tion of decreases and increases was balanced (table 2).
There was no significant association between group 
and ΔFA (χ2 = 4.9, df = 2, P = .09). Although the direc-
tion of effect for patients compared to controls indicated 
a decrease in FA over time, the difference was not sig-
nificant (B = −0.002, P = .19); additional correction for 
last year cannabis use, lifetime cannabis use, and scan 
type did not change the results of the patient-control 
comparisons (B = −0.002, P = .22; B = −0.002, P = .30 
and B = −0.002, P = .17, respectively). In siblings com-
pared to controls, there was a significant decrease in FA 
(B  =  −0.004, P  =  .04). This effect remained significant 
when controlled for scan type (B  =  −0.004, P  =  .04) 
and last year cannabis use (B  =  −0.004, P  =  .04), and 
close to significant when controlled for lifetime canna-
bis use (B = −0.003, P = .07) and history of depression 
(B = −0.003, P = .06). No significant group × sex interac-
tion in the model of ΔFA (χ2 = 0.9, df = 2, P = .62) was 
found.
Regional Group Differences in ΔFA
There was a significant group × region interaction in the 
model of ΔFA (χ2 = 105.4, df = 74, P = .01), indicating 
that group differences varied as a function of region. The 
group factor was significant in 6 of the 38 regions, of 
which 4 regions survived after Simes’ correction. Patients 
had a significant smaller FA increase in the right retrolen-
ticular part of the internal capsule (RPIC), and a decrease 
in the right cingulum and the right posterior corona radi-
ate (PCR) compared to controls. Siblings had a significant 
smaller FA increase in the right RPIC and a decrease in 
the right cingulum compared to controls. In comparison 
to patients and controls, siblings had a decrease in the left 
posterior thalamic radiation (PTR) (table 3, figure 2).
AP Medication
Within-patients analyses showed that there was a close 
to significant association between lifetime AP use (linear) 
and whole brain mean ΔFA (B = −2.5 × 10−7, P =  .08). 
Compared to low lifetime AP exposure, patients with high 
AP exposure showed significantly more FA decrease over 
time (B = −0.008, P =  .04), which was not the case for 
patients with moderate exposure (B = −0.005, P = .15). 
With regard to AP exposure over the last 3 years, a signif-
icant negative association was found between cumulative 
AP exposure (linear) and whole brain mean ΔFA over the 
last 3 years (B = −5.6 × 10−7, P =  .01). Higher levels of 
AP medication over the last 3 years predicted a stronger 
decrease in FA: moderate vs low exposure: B = −0.006, 
P = .04; high vs low exposure (B = −0.009, P = .004).
The group analyses based on AP medication sub-
groups (low, moderate, and high cumulative AP medi-
cation exposure) showed that there was a significant 
decrease in FA over time in patients with the highest level 
of AP exposure (lifetime and over the last 3 years) com-
pared to controls, but not in patients with moderate or 
low AP exposure. Siblings showed a significant stronger 
decrease in FA than patients with the lowest AP exposure 
(see supplementary table 1).
Whole Brain Group Differences in Mean FA at 
Follow-up
There was a significant association between group and 
FA at follow-up (χ2  =  10.0, df  =  2, P  =  .007): siblings 
(B = −0.007, P = .03) and patients (B = −0.010, P = .005) 
showed a significantly lower mean FA compared to the 
controls. The sibling-patient comparison was neither 
large nor significant (B = −0.001, P = .46, figure 1).
Discussion
This longitudinal DTI study showed a relatively stable 
whole brain mean FA course in patients with schizophre-
nia after the critical phase (ie, >5 years of illness duration), 
Fig. 1. Group differences in whole brain FA at follow-up. Error bars 
represent the SE of the mean ΔFA at baseline and at follow-up. FA, 
fractional anisotropy. For a color version, see this figure online.
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whereas a significant decline in mean FA was observed in 
siblings. The effect of group varied as a function of region, 
as indicated by a significant group by region interaction. 
Overall, there were more tracts showing a decrease than 
an increase over time in both patients and siblings, with a 
significant group difference in 4 WM tracts.
Findings in Patients
The study showed that, over a 3-year period, the overall 
mean FA remained stable in patients, being continuously 
lower than the mean FA of controls and siblings. This data 
is partly in line with the results of the study by Mitelman 
and colleagues (2009), examining an older (than the pres-
ent) sample (of ±41 years) of patients with a diagnosis of 
schizophrenia and healthy controls, also showing a rather 
stable FA in patients, and a greater, probably normal age-
dependent, FA decline over time in frontal, temporal, and 
parietal WM in healthy controls.20
The results suggest that major WM alterations in 
patients may have occurred in the early stages of the 
Table 2. Mean FA per Group at Baseline and at Follow-up
Mean FA
Controls Siblings Patients
Brain Region T0 T1 Δ T0 T1 Δ T0 T1 Δ
Genu of corpus callosum .7570 .7557 −.0012 .7551 .7515 −.0036 .7466 .7446 −.0020
Body of corpus callosum .7214 .7216 .0003 .7175 .7155 −.0020 .7035 .7007 −.0028
Splenium of corpus callosum .7877 .7915 .0037 .7891 .7873 −.0018 .7880 .7897 .0017
Forceps major .7004  .7042 .0038*  .6974 .6956 −.0018 .6904 .6896 −.0009
Forceps minor .5850 .5848 −.0002 .5827 .5800 −.0026 .5785 .5779 −.0006
Fornix (column and body) .5278 .5199 −.0078 .5305 .5208 −.0097 .4812 .4855 .0043
Anterior limb of internal capsule, right .6311 .6213 −.0098* .6242 .6154 −.0088* .6215 .6129 −.0086*
Anterior limb of internal capsule, left .6083 .6194 .0111* .6024 .6102 .0079* .6003 .6116 .0113*
Posterior limb of internal capsule, right .6949 .6903 −.0046 .6924 .6859 −.0065* .6954 .6906 −.0048
Posterior limb of internal capsule, left .6934  .6942 .0008 .6917 .6903 −.0014 .6977 .6953 −.0024
Retrolenticular part of internal capsule, right .5807 .5993 .0186* .5819 .5901 .0082 .5834 .5901 .0066
Retrolenticular part of internal capsule, left .5985 .5883 −.0102* .5951 .5859 −.0092* .5935 .5902 −.0033
Anterior corona radiata, right .5192 .5119 −.0073 .5150 .5043 −.0108* .5056 .4947 −.0110*
Anterior corona radiata, left .5037 .5084 .0047 .4979 .4980 .0002 .4885 .4942 .0057
Superior corona radiata, right .5267  .5297 .0030 .5239 .5240 .0001 .5186 .5191 .0006
Superior corona radiata, left .5319  .5207 −.0111* .5261 .5169 −.0091* .5235 .5121 −.0114*
Posterior corona radiata, right .5172 .5115 −.0057 .5094 .4945 −.0150* .5062 .4873 −.0189*
Posterior corona radiata, left .5010  .5134 .0125* .4892 .5018 .0125* .4835 .4999 .0163*
Posterior thalamic radiation, right .6269 .6260 −.0009 .6207 .6162 −.0045 .6180 .6081 −.0099
Posterior thalamic radiation, left .6179 .6255 .0076  .6105 .6094 −.0011 .6011 .6123 .0111
Sagittal stratuma, right .5732 .5744 .0012  .5687 .5637 −.0050 .5656 .5635 −.0020
Sagittal stratuma, left .5706 .5746 .0040 .5609 .5625 .0016 .5617 .5641 .0024
External capsule, right .4769 .4770 .0001 .4741 .4690 −.0050 .4711 .4679 −.0032
External capsule, left .4731  .4755 .0024 .4679 .4698 .0020 .4652 .4715 .0063
Cingulum (cingulate gyrus), right .6104 .6403 .0299* .6099 .6333 .0233* .6072 .6378 .0305*
Cingulum (cingulate gyrus), left .6391  .6048 −.0343* .6344 .6016 −.0328* .6344 .6023 −.0320*
Cingulum (hippocampus), right .5556 .5585 .0029 .5602 .5393 −.0210* .5535 .5445 −.0090
Cingulum (hippocampus), left .5486 .5702 .0216* .5421 .5552 .0131 .5417 .5599 .0182*
Fornix, stria terminalis, right .5581 .5806 .0225* .5547 .5701 .0153* .5454 .5671 .0217*
Fornix, stria terminalis, left .5625 .5562 −.0063 .5590 .5433 −.0156* .5509 .5426 −.0084
Superior longitudinal fasciculus, right .5298 .5313 .0015 .5325 .5297 −.0028 .5320 .5241 −.0079
Superior longitudinal fasciculus, left .5303 .5243 −.0060 .5305 .5258 −.0047 .5271 .5233 −.0038
Superior fronto-occipital fasciculus, right .5380 .5308 −.0072 .5329 .5281 −.0048 .5214 .5155 −.0060
Superior fronto-occipital fasciculus, left .5276 .5252 −.0023  .5189 .5188 −.0001 .5097 .5123 .0026
Uncinate fasciculus, right .5523 .5516 −.0006 .5393 .5413 .0019 .5395 .5387 −.0008
Uncinate fasciculus, left .5263  .5179 −.0084  .5109 .5074 −.0035 .5071 .5108 .0037
Tapetum, right .6164 .6121 −.0042 .5907 .5824 −.0083 .5910 .5714 −.0196*
Tapetum, left .6345 .6343 −.0002 .6106 .5983 −.0124 .5942 .5812 −.0130
Note: Δ = mean FA difference (mean FA follow-up − mean FA baseline), with values in italics representing FA decreases and bold 
representing FA increases. FA, fractional anisotropy.
aIncl. inferior longitudinal fasciculus and inferior fronto-occipital fasciculus.
*Results of a within-group paired t-test examining significant within group ΔFA differences per brain region (P < .05), accounting for a 
false discovery rate with the Simes’ procedure (38 regions × 3 groups) (*PSimes < .003).
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illness, as described previously,15 without ongoing pro-
gression. Alternatively, WM may have been modulated 
by AP medication, which was supported in the current 
study by the small but significant negative within-group 
effect of AP medication on ΔFA, with a dose-response 
effect for AP exposure over the last 3  years. Moreover, 
patients with the highest AP exposure levels (lifetime, as 
well as over the last 3 years) had a significant decrease in 
FA over time compared to controls, whereas this was not 
the case for patients with low or moderate AP exposure 
compared to controls.
Together with the widespread microstructural WM alter-
ations presented in cross-sectional studies of at-risk popu-
lations and first episode psychotic patients,5 the data add 
Table 3. Group Comparisons in Regions With a Significant Group Effect
Between-Group Effect Patient-Control Sibling-Control Patient-Sibling
Brain Region (χ2, df = 2, P) (B, P) (B, P) (B, P)
Retrolenticular part of internal capsule, right 11.8, .003† −0.01, .001* −0.01, .008* −0.003, .49
Posterior corona radiata, right 10.5, .005† −0.01, .001* −0.009, .03 −0.004, .29
Posterior thalamic radiation, right 9.0, .01 −0.01, .003 −0.004, .27 −0.007, .05
Posterior thalamic radiation, left 14.2, .0008† 0.004, .31 −0.009, .01* 0.01, .0003*
Cingulum, right 19.6, .0001† −0.01, .01* −0.02, 9.7 × 10−6* 0.01, .05
Superior longitudinal fasciculus, right 9.4, .009 −0.01, .002 −0.004, 0.15 −0.005, .08
Note: The χ2 and the P-values represent the significant results of the between-group factor analyses per region in multilevel modeling 
(†PSimes < .005). B and P-values of the individual group comparisons are shown (*PSimes < .02). Analyses are controlled for age, sex, 
handedness, level of education, and scan interval.
Fig. 2. Group × region interactions in the model of ΔFA. Group differences in mean ΔFA in 4 WM tracts are displayed (PSimes < .02), 
corresponding with table 3. Error bars represent the SE of the mean ΔFA at baseline and at follow-up. FA, fractional anisotropy. For a 
color version, see this figure online.
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to the evidence for an early developmental origin of WM 
alterations in schizophrenia.8 Indeed, a significant progres-
sive reduction in FA of the left frontal WM has been found 
in UHR subjects who later developed psychosis compared 
to UHR subjects who did not make the transition.17
Despite the overall mean FA being constant, most 
WM tracts in the 3 groups showed minor (nonsignificant) 
changes in individual FA trajectories (table 2). WM tracts 
develop at different ages in different curvilinear patterns 
(inverted U-shape), with FA increases from the newborn 
period to adolescence, shows decelerated maturation 
until mid-adulthood and subsequently displays more 
rapid decline during old age.40,41 The WM tracts of the 
controls in this study may be at the top of the normal 
age trajectory curve because of the proportionally equal 
number of WM tracts with an FA increase and decrease. 
In contrast, patients showed a higher number of WM 
tracts with FA decreases, suggesting an altered develop-
mental pattern, ie, an earlier than expected age-related 
decrease of WM. Specifically, a smaller FA increase in 
the RPIC and decrease in the PCR and the cingulum (all 
right-sided) was found in patients. These tracts have face-
validity, as they are frequently described in relation to 
fronto-temporal disconnection in schizophrenia.4,42
Findings in Siblings
This is the first longitudinal study showing whole brain 
WM alterations over time in a sample of healthy partici-
pants at higher than average risk for psychotic disorder 
(siblings of patients with psychotic disorder). At base-
line, there was no significant difference in whole brain 
mean FA between siblings and controls, whereas such a 
difference was apparent between siblings and patients.24 
At follow-up, siblings showed a significant lower whole 
brain mean FA with respect to the controls and the sig-
nificant difference with patients was no longer apparent. 
The difference at follow-up was confirmed by a signifi-
cant FA decrease over time in siblings compared to con-
trols, which was not observed in patients. At the level of 
individual tracts, almost two-third of the WM tracts in 
siblings revealed a decrease in FA over time, compared 
to the more balanced ratio of FA increases and decreases 
in the controls. Specifically, the left PTR and the right 
cingulum revealed a significant decrease of mean FA over 
time in siblings, whereas controls showed an increase. The 
PTR has previously been associated with schizophre-
nia,15,43 eg, with impaired emotional self-awareness.44 To 
our knowledge subtle FA decreases in the PTR have only 
been associated with bipolar45 but not psychosis liabil-
ity. As mentioned before, all WM tracts have different 
maturational trajectories.46 The cingulum has one of the 
most prolonged maturation periods and reaches its peak 
FA only after 40 years of age.47 Given the mean age of 
34 years in the siblings and of 32 years in the patients, 
the earlier than expected FA decline may reflect disturbed 
WM maturation from an early age, suggesting a neuro-
developmental origin. Alternatively, it may suggest pro-
gression associated with illness vulnerability, though the 
findings in the patients did not support this.
Decreased anisotropy in the cingulum has also been 
described in several cross-sectional studies in patients 
with schizophrenia48,49 and in the longitudinal study of 
Mitelman and colleagues (2009), where the left anterior 
cingulate gyrus was 1 of the 2 areas that showed a greater 
decline in FA in patients with schizophrenia compared 
to healthy participants.20 Regarding the present finding 
of a patient-control difference in this region, current and 
previous cross-sectional DTI findings50 in siblings may be 
suggestive of a WM intermediate phenotype.
Clinically, WM alterations in (sub-)regions of the 
cingulum have been related to impairments in impulsiv-
ity51 and executive functioning52 as well as to positive 
and negative symptoms53 in patients with schizophrenia. 
As mild cognitive alterations are present in non-affected 
relatives,54,55 it may be hypothesized that subclinical 
expression of symptoms are associated with this WM 
intermediate phenotype, which will be the topic of fur-
ther investigation.
Methodological Considerations
Although the present study has several strengths, such as 
the rather large sample size, the longitudinal design cover-
ing a 3-year period, and the inclusion of both patients and 
their healthy siblings, there are some limitations that need 
to be taken into account when interpreting the results.
AP medication may have an effect on WM.15 Until 
now, only a handful of longitudinal diffusion studies have 
been published, examining (short-term) effects of AP 
medication on microstructural WM (pre-post treatment 
measurements).56–59 The results of the present study were 
supportive of an effect of (especially the highest) cumula-
tive medication exposure levels on FA change over time, 
both in within-patients analyses and in between-group 
analyses based on AP exposure subgroups (with one-third 
of the patients in each subgroup). However, as the FA 
change in siblings, who were not using AP medication, 
was also significantly different from controls, AP exposure 
may be one of the contributing factors of microstructural 
WM alteration in patients with psychotic disorder.
The same applies to drug use. The present study sam-
ple was not drug-free which may have influenced our 
results. Study results differ with respect to the potential 
influence of cannabis use on WM alterations in patients 
with schizophrenia.60 Although the significant results in 
the control-sibling comparison remained stable after con-
trolling for cannabis use (last year), lifetime cannabis use 
appeared to exert some influence, although the effect size 
was not affected much.
Given the absence of (1) differences in alcohol con-
sumption across groups, (2) other drug use in the controls 
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and siblings, and (3) effects of other drug use on micro-
structural WM in the baseline study,24 sensitivity analy-
ses for these substances were not considered additional 
informative.
Inconsistencies in the results of the limited longitudinal 
studies conducted to date may be due to varying patient 
samples,17,20 as well as varying acquisition and analys-
ing techniques. Although Reis Marques and colleagues 
(2012) used TBSS, their procedures and analyses differed 
from the present study.18 Furthermore, limited knowledge 
is available about the margins of across-session reproduc-
ibility errors.61,62 As this was the first longitudinal DTI 
study including healthy siblings, we used a whole brain, 
voxel-based analyses, given the fact that evidence for dif-
ferential WM regional time-trajectories is missing to date. 
The results of the group by region interactions are thus 
hypothesis-generating and may be of use in future longi-
tudinal studies that examine individual WM tracts within 
distinct development trajectories.
Supplementary Material
Supplementary material is available at http://schizophre-
niabulletin.oxfordjournals.org.
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